Mission Wealth Management LP Decreases Holdings in Anixa Biosciences, Inc. (NASDAQ:ANIX)

Mission Wealth Management LP lowered its position in Anixa Biosciences, Inc. (NASDAQ:ANIX) by 7.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 469,517 shares of the company’s stock after selling 40,000 shares during the quarter. Mission Wealth Management LP’s holdings in Anixa Biosciences were worth $1,089,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in Anixa Biosciences in the third quarter valued at $34,000. Westside Investment Management Inc. boosted its position in shares of Anixa Biosciences by 151.8% in the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after buying an additional 21,100 shares in the last quarter. Tyler Stone Wealth Management boosted its position in shares of Anixa Biosciences by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after buying an additional 21,008 shares in the last quarter. Finally, International Assets Investment Management LLC increased its holdings in Anixa Biosciences by 170.0% during the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after acquiring an additional 23,800 shares in the last quarter. 29.13% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Anixa Biosciences

In related news, Director Lewis H. Titterton, Jr. bought 10,000 shares of the stock in a transaction that occurred on Friday, January 17th. The stock was purchased at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the completion of the acquisition, the director now owns 922,334 shares in the company, valued at $2,370,398.38. This trade represents a 1.10 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Amit Kumar purchased 43,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were bought at an average cost of $2.23 per share, with a total value of $95,890.00. Following the transaction, the chief executive officer now directly owns 559,925 shares of the company’s stock, valued at $1,248,632.75. The trade was a 8.32 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders acquired 75,289 shares of company stock worth $177,021. Insiders own 25.30% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on ANIX. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a report on Wednesday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a report on Tuesday, February 18th.

Anixa Biosciences Trading Up 1.8 %

Shares of ANIX stock opened at $2.89 on Wednesday. Anixa Biosciences, Inc. has a twelve month low of $2.07 and a twelve month high of $4.20. The company has a market capitalization of $93.05 million, a price-to-earnings ratio of -7.41 and a beta of 0.93. The firm has a 50-day moving average price of $2.76 and a 200 day moving average price of $3.04.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings data on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. As a group, research analysts predict that Anixa Biosciences, Inc. will post -0.41 earnings per share for the current year.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.